VivoSeq
Neurology

Limb-Girdle Muscular Dystrophy Type 2i (LGMD2I)

1

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) is an early-stage landscape with 1 program across 0 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

BBP-418

ML Bio Solutions, Inc.

Approved
No programs

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants With Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)
Active, not recruiting·MML Bio Solutions, Inc.·Phase 3·NCT07678775·107 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)